Glowing dye could replace radioactive tracers in breast cancer surgery
NCT ID NCT07311278
First seen Jan 10, 2026
Summary
This study tests whether a fluorescent dye called indocyanine green (ICG) can replace the current radioactive tracer (technetium) for finding sentinel lymph nodes in breast cancer patients. About 493 women with early-stage breast cancer will take part. Surgeons will first use the standard method, then learn to use ICG, comparing how well each method finds the lymph nodes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Antoni van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands
-
Bernhoven Ziekenhuis
Uden, Netherlands
-
Erasmus Medisch Centrum
Rotterdam, Netherlands
-
FlevoZiekenhuis
Almere Stad, Netherlands
-
HagaZiekenhuis
The Hague, Netherlands
-
Isala Ziekenhuis
Zwolle, Netherlands
-
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands
-
Maastricht Universitair Medisch Centrum
Maastricht, Netherlands
-
Ospedale Pederzoli
Peschiera del Garda, Italy
-
Reinier de Graaf Gasthuis
Delft, Netherlands
-
Van Weel-Bethesda Ziekenhuis
Dirksland, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Indocyanine green (ICG) dye
What this could lead to
If successful, this could make sentinel lymph node detection safer and more accessible by replacing radioactive tracers with a fluorescent dye.
What could go wrong
This is an implementation study, not a test of effectiveness. ICG may not work as well as technetium in all patients, and results may vary across hospitals.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.